What is resveratrol?

Resveratrol is a naturally occurring polyphenol that can act as a phytoestrogen. It is found in berries, nuts, grapes and other plants. Research in animals and humans has investigated whether resveratrol may have effects related to inflammation, oxidative stress, metabolism and brain health. However, much of the human evidence remains limited by small samples, short study durations or other methodological limitations.

Resveratrol can influence some cellular pathways that are also affected by calorie restriction, which has led researchers to investigate possible effects on healthy ageing and longevity. Results from animal and non-human-primate studies have been mixed, and it has not been established that resveratrol extends human lifespan.

How does resveratrol work?

Several mechanisms have been proposed to explain possible effects on mood, anxiety and brain function. Experimental studies suggest antioxidant and anti-inflammatory actions and have examined potential neuroprotective effects in models of Parkinson’s disease, Huntington’s disease, multiple sclerosis, Alzheimer’s disease and other neurodegenerative disorders. These experimental findings should not be interpreted as proof that resveratrol treats these diseases in humans.

Animal studies have also reported antidepressant- and anxiolytic-like effects, including mechanisms involving phosphodiesterase-4. Other research has explored oxidative damage, metabolic health, cerebral blood flow, blood–brain-barrier function and epigenetic effects. These remain active areas of investigation.

How might resveratrol affect cognitive function?

Results from animal studies and a limited number of human trials have generated interest in resveratrol as a possible cognitive-health compound in healthy adults and as a research candidate in Alzheimer’s disease and other neurodegenerative disorders.

Evidence in healthy people is inconsistent, probably in part because studies have used different doses, durations and cognitive tests. In short-term studies, healthy men taking 250–500 mg showed dose-related increases in cerebral blood flow without clear improvements in cognitive performance. In one four-week study, men taking 500 mg reported reduced fatigue but no clear cognitive improvement.

In a 26-week study of healthy older overweight adults, supplementation with resveratrol and quercetin was associated with improvements in memory, hippocampal functional connectivity and brain glucose metabolism. A systematic review of randomised controlled trials reported small-to-moderate cognitive improvements in some older adults and postmenopausal women taking approximately 150–200 mg daily for at least 14 weeks, with some findings correlating with increased cerebral blood flow. These findings are not sufficiently consistent to establish resveratrol as a treatment for cognitive decline.

Resveratrol and Alzheimer’s disease research

Polyphenols, including resveratrol, are increasingly studied for possible roles in neurodegenerative disease, but clinical research remains early. In a 52-week, randomised, double-blind, placebo-controlled phase 2 trial involving 119 people with mild-to-moderate Alzheimer’s disease, participants received placebo or escalating doses of resveratrol, beginning at 500 mg per day and increasing every 13 weeks to a maximum of 2,000 mg per day.

The study measured Alzheimer’s biomarkers, volumetric MRI and clinical outcomes. Some biomarker changes—including changes involving cerebrospinal-fluid markers and MMP-9—were observed in the resveratrol group. These findings generated hypotheses about blood–brain-barrier permeability, inflammation and neuroprotection, but they did not establish resveratrol as an effective Alzheimer’s treatment. Nausea, diarrhoea and weight loss were among the more common adverse effects. Further research is required to understand the clinical significance of the biomarker findings.

Resveratrol and depression

Research into resveratrol as a possible intervention for depression is still at an early stage. Cell and animal studies suggest possible neuroprotective effects against changes associated with oxidative stress and inflammation, but evidence in humans is insufficient to recommend resveratrol as an antidepressant treatment.

Is resveratrol safe?

Resveratrol is generally reported to be tolerated at doses used in many studies, but adverse effects can include nausea, diarrhoea and weight loss. Higher experimental doses have produced more side effects. Resveratrol can affect drug-metabolising enzymes and may interact with medicines; people taking medication, pregnant or breastfeeding people, and those with medical conditions should discuss supplementation with a qualified healthcare professional.

Getting the most from resveratrol supplements

A major research challenge is resveratrol’s relatively low bioavailability. It is rapidly metabolised, and its stability, solubility and exposure to light and heat can influence formulations. Researchers have investigated combinations with compounds such as piperine as well as delivery systems including lipid carriers, liposomes, nanoemulsions and other formulations. Early results are interesting, but more human research is needed before an optimal formulation or dose can be defined.

Individual differences in genetics, age, sex, diet, microbiome, health status and medication use may also influence exposure and effects. There is therefore no single evidence-based “minimum effective dose” that can be recommended for all people or all proposed uses.

Resveratrol is promising—but not proven

Resveratrol is a scientifically interesting compound being investigated in metabolic, cardiovascular and neuropsychiatric research. Work on cognitive decline, Alzheimer’s disease, other neurodegenerative disorders and depression remains preliminary. Much of the evidence comes from laboratory and animal research, while human trials are still relatively few and often small.

Large, long-term, placebo-controlled human trials are needed to clarify safety, clinically meaningful benefits, interactions, bioavailability and appropriate dosing. Resveratrol should not be used as a substitute for established medical treatment.

Sources

  1. Adeghate E, Donath T, Adem A. (2013). Alzheimer disease and diabetes mellitus: do they have anything in common? Curr Alzheimer Res. 10:609–617.
  2. Amri A, Chaumeil JC, Sfar S, Charrueau C. (2012). Administration of resveratrol: What formulation solutions to bioavailability limitations? J Control Release. 158:182–193.
  3. Baur JA, Sinclair DA. (2006). Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 5:493–506.
  4. Blanchet J, Longpre F, Bureau G, Morissette M, DiPaolo T, et al. (2008). Resveratrol, a red wine polyphenol, protects dopaminergic neurons in MPTP-treated mice. Prog Neuropsychopharmacol Biol Psychiatry. 32:1243–1250.
  5. Chimento A, De Amicis F, Sirianni R, Stefania M, et al. (2019). Progress to Improve Oral Bioavailability and Beneficial Effects of Resveratrol. Int J Mol Sci. 20(6):1381.
  6. Colman RJ, Beasley TM, Kemnitz JW, Johnson SC, Weindruch R, Anderson RM. (2014). Caloric restriction reduces age-related and all-cause mortality in rhesus monkeys. Nat Commun. 5:3557.
  7. Cottart CH, Nivet-Antoine V, Beaudeux JL. (2014). Review of recent data on the metabolism, biological effects, and toxicity of resveratrol in humans. Mol Nutr Food Res. 58:7–21.
  8. De Santi SC, Pietrabissa A, Spisni R, Mosca F, Pacifici GM. (2000). Sulphation of resveratrol, a natural compound present in wine, and its inhibition by natural flavonoids. Xenobiotica. 30:857–866.
  9. Dhakal S, Kushairi N, Phan CW, Adhikari B, Sabaratnam V, et al. (2019). Dietary Polyphenols: A Multifactorial Strategy to Target Alzheimer’s Disease. Int J Mol Sci. 20(20):5090.
  10. Farhan M, Ullah MF, Faisal M, Farooqi AA, Sabitaliyevich UY, et al. (2019). Differential Methylation and Acetylation as the Epigenetic Basis of Resveratrol’s Anticancer Activity. Medicines (Basel). 6(1):24.
  11. Foti Cuzzola V, Ciurleo R, Giacoppo S, Marino S, Bramanti P. (2011). Role of resveratrol and its analogues in the treatment of neurodegenerative diseases. CNS Neurol Disord Drug Targets. 10:849–862.
  12. Johnson JJ, Nihal M, Siddiqui IA, Scarlett CO, Bailey HH, et al. (2011). Enhancing the bioavailability of resveratrol by combining it with piperine. Mol Nutr Food Res. 55:1169–1176.
  13. Kennedy DO, Wightman EL, Reay JL, Lietz G, Okello EJ, et al. (2010). Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans. Am J Clin Nutr. 91:1590–1597.
  14. Kim D, Nguyen MD, Dobbin MM, Fischer A, Sananbenesi F, et al. (2007). SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer’s disease and amyotrophic lateral sclerosis. EMBO J. 26:3169–3179.
  15. Kumar P, Padi SS, Naidu PS, Kumar A. (2006). Effect of resveratrol on 3-nitropropionic acid-induced biochemical and behavioural changes. Behav Pharmacol. 17:485–492.
  16. La Porte C, Voduc N, Zhang G, Seguin I, Tardiff D, Singhal N, Cameron DW. (2010). Steady-State pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily. Clin Pharmacokinet. 49:449–454.
  17. Mattison JA, Roth GS, Beasley TM, Tilmont EM, Handy AM, et al. (2012). Impact of caloric restriction on health and survival in rhesus monkeys. Nature. 489:318–321.
  18. Soni M, Rahardjo TB, Soekardi R, et al. (2014). Phytoestrogens and cognitive function: a review. Maturitas. 77(3):209–220.
  19. Menegas S, Ferreira CL, Cararo JH, Gava FF, et al. (2019). Resveratrol protects the brain against oxidative damage in a dopaminergic animal model of mania. Metab Brain Dis. 34(3):941–950.
  20. Mercken EM, Carboneau BA, Krzysik-Walker SM, de Cabo R. (2012). Of mice and men: the benefits of caloric restriction, exercise, and mimetics. Ageing Res Rev. 11:390–398.
  21. Miller RA, Harrison DE, Astle CM, Baur JA, Boyd AR, et al. (2011). Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J Gerontol A Biol Sci Med Sci. 66:191–201.
  22. Moussa C, Hebron M, Huang X, Ahn J, Rissman RA, et al. (2017). Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease. J Neuroinflammation. 14(1):1.
  23. Pearson KJ, Baur JA, Lewis KN, Peshkin L, Price NL, et al. (2008). Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab. 8:157–168.
  24. Popat R, Plesner T, Davies F, Cook G, Cook M, et al. (2013). A phase 2 study of SRT501 (resveratrol) with bortezomib for relapsed/refractory multiple myeloma. Br J Haematol. 160:714–717.
  25. Santos AC, Veiga F, Ribeiro AJ. (2011). New delivery systems to improve the bioavailability of resveratrol. Expert Opin Drug Deliv. 8(8):973–990.
  26. Shindler KS, Ventura E, Dutt M, Elliott P, Fitzgerald DC, Rostami A. (2010). Oral resveratrol reduces neuronal damage in a model of multiple sclerosis. J Neuroophthalmol. 30:328–339.
  27. Smoliga JM, Colombo ES, Campen MJ. (2013). A healthier approach to clinical trials evaluating resveratrol for primary prevention of age-related diseases. Aging (Albany NY). 5:495–506.
  28. Soni M, White LR, Kridawati A, Bandelow S, Hogervorst E. (2016). Phytoestrogen consumption and risk for cognitive decline and dementia. J Steroid Biochem Mol Biol. 160:67–77.
  29. Strong R, Miller RA, Astle CM, Baur JA, de Cabo R, et al. (2013). Evaluation of resveratrol, green tea extract, curcumin, oxaloacetic acid, and medium-chain triglyceride oil on life span. J Gerontol A Biol Sci Med Sci. 68:6–16.
  30. Sun AY, Wang Q, Simonyi A, Sun GY. (2010). Resveratrol as a therapeutic agent for neurodegenerative diseases. Mol Neurobiol. 41:375–383.
  31. Zhu X, Li W, Li Y, Xu W, Yuan Y, et al. (2019). The antidepressant- and anxiolytic-like effects of resveratrol: involvement of phosphodiesterase-4D inhibition. Neuropharmacology. 153:20–31.
  32. Turner RS, Thomas RG, Craft S, van Dyck CH, Mintzer J, et al. (2015). A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology. 85(16):1383–1391.
  33. Wang F, Wang J, An J, Yuan G, Hao X, Zhang Y. (2018). Resveratrol ameliorates depressive disorder through the NETRIN1-mediated ERK/cAMP pathway. Mol Med Rep. 17(3):4611–4618.
  34. Wightman EL, Haskell-Ramsay CF, Reay JL, Williamson G, Dew T, et al. (2015). Effects of chronic trans-resveratrol supplementation on cognitive function, mood, sleep, health and cerebral blood flow. Br J Nutr. 114(9):1427–1437.
  35. Wightman EL, Reay JL, Haskell CF, Williamson G, Dew TP, Kennedy DO. (2014). Effects of resveratrol alone or with piperine on cerebral blood flow and cognitive performance. Br J Nutr. 112:203–213.
  36. Witte AV, Kerti L, Margulies DS, Floel A. (2014). Effects of Resveratrol on Memory Performance, Hippocampal Functional Connectivity, and Glucose Metabolism in Healthy Older Adults. J Neurosci. 34:7862–7870.
  37. Zaw T, Howe P, Wong R. (2017). Does phytoestrogen supplementation improve cognition in humans? A systematic review. Ann N Y Acad Sci. 1403(1):150–163.